This company listing is no longer active
DBVT.F Stock Overview
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
DBV Technologies S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €2.80 |
52 Week High | €2.80 |
52 Week Low | €2.80 |
Beta | 1.56 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | -96.59% |
Change since IPO | -90.93% |
Recent News & Updates
Recent updates
Shareholder Returns
DBVT.F | US Biotechs | US Market | |
---|---|---|---|
7D | 0% | -1.3% | -0.08% |
1Y | n/a | 10.6% | 27.7% |
Return vs Industry: Insufficient data to determine how DBVT.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how DBVT.F performed against the US Market.
Price Volatility
DBVT.F volatility | |
---|---|
DBVT.F Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 11.8% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: DBVT.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DBVT.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2002 | 88 | Daniel Tassé | https://www.dbv-technologies.com |
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow’s milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen’s egg allergy; and booster vaccine for Bordetella pertussis.
DBV Technologies S.A. Fundamentals Summary
DBVT.F fundamental statistics | |
---|---|
Market cap | US$472.59m |
Earnings (TTM) | -US$77.45m |
Revenue (TTM) | US$8.33m |
56.7x
P/S Ratio-6.1x
P/E RatioIs DBVT.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DBVT.F income statement (TTM) | |
---|---|
Revenue | US$8.33m |
Cost of Revenue | US$0 |
Gross Profit | US$8.33m |
Other Expenses | US$85.78m |
Earnings | -US$77.45m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 03, 2022
Earnings per share (EPS) | -0.82 |
Gross Margin | 100.00% |
Net Profit Margin | -929.91% |
Debt/Equity Ratio | 0.4% |
How did DBVT.F perform over the long term?
See historical performance and comparison